GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses.
1 report, 1 independent
Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- GSK is advancing its experimental influenza vaccine into late-stage development following a portfolio review.Sub-event
- Moderna's vaccine demonstrated superior efficacy compared to GSK's flu shot on July 1, 2025.Sub-event
GSK, Moderna, and Sinovac are innovating in the influenza vaccine market after Phase 3 trials showed strong immune responses.1 source
Keep exploring
The entities involved
-
Moderna
American biotechnology company
-
GlaxoSmithKline
company in Tokyo, Japan
Related events
- Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Moderna presented vaccine results at the ESMO meeting in Madrid, with RBC Capital Markets covering the company.
Coverage
Newest first; wire copies grouped- GlobeNewswireInfluenza Vaccine Market Research Report 2025-2030 Featuring GSK, Abbott, Pfizer, AstraZeneca, Sanofi, Moderna, CSL, Emergent BioSolutions, BIKEN, Serum Institute of India, Sinovac, GC Biopharma The